CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Pasi A. Jänne; David Planchard; Kunihiko Kobayashi; Ying Cheng; Chee Khoon Lee; Natalia Valdiviezo; К. К. Лактионов; Tsung‐Ying Yang; Yan Yu; Terufumi Kato; Liyan Jiang; Busyamas Chewaskulyong; Sarayut Lucien Geater; Jean-Marc Maurel; Carlos A. Rojas; Toshiaki Takahashi; Libor Havel; Frances A. Shepherd; Kentaro Tanaka; Dana Ghiorghiu; Neha P. Amin; Elena Armenteros-Monterroso; Xiangning Huang; Ammar Chaudhry; James Chih‐Hsin Yang

doi:10.1200/jco.23.02219

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jänne et al. (2023) studied this question.

synapsesocial.com/papers/69df1a033b0ba53fb37a14cb https://doi.org/10.1200/jco.23.02219

View Full Paper

Ask AI

Bookmark

Share

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading